Cargando…

Enhanced SARS-CoV-2 Antibody Response After a Third Heterologous Vector Vaccine Ad26COVS1 Dose in mRNA Vaccine-Primed Kidney Transplant Recipients

Detalles Bibliográficos
Autores principales:	Schimpf, Judith, Davidovic, Tamara, Abbassi-Nik, Armin, Sprenger-Mähr, Hannelore, Lhotta, Karl, Zitt, Emanuel
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Health Archive
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8980220/ https://www.ncbi.nlm.nih.gov/pubmed/35391899 http://dx.doi.org/10.3389/ti.2022.10357

Ejemplares similares

Humoral and Cellular Immune Response After a 3-Dose Heterologous SARS-CoV-2 Vaccination Using the mRNA-BNT162b2 and Viral Vector Ad26COVS1 Vaccine in Hemodialysis Patients
por: Davidovic, Tamara, et al.
Publicado: (2022)

Humoral Response in SARS-CoV-2 Convalescent Compared to Vaccinated Kidney Transplant Patients
por: Schimpf, Judith, et al.
Publicado: (2022)

De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis
por: Davidovic, Tamara, et al.
Publicado: (2021)

Waning humoral response 6 months after SARS-CoV-2 vaccination with the mRNA-BNT162b2 vaccine in hemodialysis patients: time for a boost
por: Davidovic, Tamara, et al.
Publicado: (2021)

The Safety and Immunogenicity of the mRNA-BNT162b2 SARS-CoV-2 Vaccine in Hemodialysis Patients
por: Zitt, Emanuel, et al.
Publicado: (2021)

Acute Kidney Injury Treated with Dialysis outside the Intensive Care Unit: A Retrospective Observational Single-Center Study
por: Sprenger-Mähr, Hannelore, et al.
Publicado: (2016)

SARS-CoV-2 infection and recurrence of anti-glomerular basement disease: a case report
por: Winkler, Alexander, et al.
Publicado: (2021)

Efficacy and safety of body weight-adapted oral cholecalciferol substitution in dialysis patients with vitamin D deficiency
por: Zitt, Emanuel, et al.
Publicado: (2015)

Successful Treatment of Focal Segmental Glomerulosclerosis after Kidney Transplantation with Plasma Exchange and Abatacept in a Patient with Juvenile Rheumatoid Arthritis
por: Sprenger-Mähr, Hannelore, et al.
Publicado: (2016)

Treatment of Concurrent Thrombotic Thrombocytopenic Purpura and Graves' Disease: A Report on Two Cases
por: Lhotta, Karl, et al.
Publicado: (2018)

A hemodialysis patient with bone disease after pregnancy: a case report
por: Sprenger-Mähr, Hannelore, et al.
Publicado: (2019)

SARS-CoV-2 Vaccination-Induced Immunogenicity in Heart Transplant Recipients
por: Memenga, Felix, et al.
Publicado: (2023)

Humoral and cellular immunogenicity of homologous and heterologous booster vaccination in Ad26.COV2.S-primed individuals: Comparison by breakthrough infection
por: Hyun, Hakjun, et al.
Publicado: (2023)

Differential immunogenicity of homologous versus heterologous boost in Ad26.COV2.S vaccine recipients
por: Khoo, Nicholas Kim Huat, et al.
Publicado: (2022)

Optimizing COVID-19 Vaccination Strategy in Pediatric Kidney Transplant Recipients: Humoral and Cellular Response to SARS-CoV-2 mRNA Vaccination
por: Nel, Isabelle, et al.
Publicado: (2023)

Heterologous Ad26.COV2.S Prime and mRNA-Based Boost COVID-19 Vaccination Regimens: The SWITCH Trial Protocol
por: Sablerolles, Roos S. G., et al.
Publicado: (2021)

Protective Effect of Vaccine Doses and Antibody Titers Against SARS-CoV-2 Infection in Kidney Transplant Recipients
por: Chen, Chien-Chia, et al.
Publicado: (2023)

Immunogenicity and Reactogenicity of Vaccine Boosters after Ad26.COV2.S Priming
por: Sablerolles, Roos S.G., et al.
Publicado: (2022)

Humoral response to heterologous prime‐booster vaccination in heart transplant recipients aged 18–70 years primed with a viral vector SARS‐CoV‐2 vaccine
por: Tanner, Richard, et al.
Publicado: (2022)

Heterologous prime boost COVID 19 vaccination
por: Launay, O., et al.
Publicado: (2022)

The Effects of Heterologous Immunization with Prime-Boost COVID-19 Vaccination against SARS-CoV-2
por: Ho, Tzu-Chuan, et al.
Publicado: (2021)

Immune Response to Third Dose BNT162b2 COVID-19 Vaccine Among Kidney Transplant Recipients—A Prospective Study
por: Yahav, Dafna, et al.
Publicado: (2022)

Comparison of mRNA-1273 and BNT162b2 SARS-CoV-2 mRNA Vaccine Immunogenicity in Kidney Transplant Recipients
por: Haller, Maria C., et al.
Publicado: (2022)

Therapeutic Drug Monitoring of Mycophenolic Acid Identifies Kidney Transplant Recipients Responsive to Two SARS-CoV-2 mRNA Vaccine Doses
por: von Moos, Seraina, et al.
Publicado: (2023)

SARS-CoV2 mRNA Vaccine-Specific B-, T- and Humoral Responses in Adolescents After Kidney Transplantation
por: Sattler, Arne, et al.
Publicado: (2022)

Association of neutralizing breadth against SARS-CoV-2 with inoculation orders of heterologous prime-boost vaccines
por: Zhu, Yufang, et al.
Publicado: (2022)

A Pilot Single-Blinded, Randomized, Controlled Trial Comparing BNT162b2 vs. JNJ-78436735 Vaccine as the Third Dose After Two Doses of BNT162b2 Vaccine in Solid Organ Transplant Recipients
por: Natori, Yoichiro, et al.
Publicado: (2023)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
por: Goh, Yun Shan, et al.
Publicado: (2022)

Heterologous booster vaccination with CoronaVac following prime vaccination with mRNA vaccine
Publicado: (2023)

Diagnostik und Therapie IgA Nephropathie – 2023
por: Schimpf, Judith, et al.
Publicado: (2023)

Immunogenicity and reactogenicity after heterologous prime-boost vaccination with CoronaVac and ChAdox1 nCov-19 (AZD1222) vaccines
por: Cohen, Guy, et al.
Publicado: (2022)

Potency of an HIV-SAM™ vaccine in a heterologous prime-boost vaccination regimen
por: Banerjee, K, et al.
Publicado: (2012)

Socioeconomic Differences in SARS-CoV-2 Infection and Vaccination in Germany: A Seroepidemiological Study After One Year of COVID-19 Vaccination Campaign
por: Bartig, Susanne, et al.
Publicado: (2023)

Outcome of COVID-19 in Kidney Transplant Recipients Through the SARS-CoV-2 Variants Eras: Role of Anti-SARS-CoV-2 Monoclonal Antibodies
por: Papadimitriou-Olivgeris, Matthaios, et al.
Publicado: (2022)

Heterologous Prime-Boost Vaccination with Commercial FMD Vaccines Elicits a Broader Immune Response than Homologous Prime-Boost Vaccination in Pigs
por: Kim, Jaejo, et al.
Publicado: (2023)

Reactogenicity and immunogenicity of heterologous prime-boost immunization with COVID-19 vaccine
por: Nguyen, Thuy Trang, et al.
Publicado: (2022)

Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
por: Shaw, Robert H, et al.
Publicado: (2021)

Heterologous prime-boost vaccination against COVID-19: is it safe and reliable?
por: Choudhary, Om Prakash, et al.
Publicado: (2021)

Tu1269: IMMUNOGENICITY AND SAFETY OF HETEROLOGOUS VERSUS HOMOLOGOUS PRIME-BOOST REGIMENS WITH ADENOVIRAL VECTORED AND MRNA SARS-COV-2 VACCINE IN LIVER TRANSPLANT RECIPIENTS
por: Sriphoosanaphan, Supachaya, et al.
Publicado: (2022)

Immunogenicity of a Heterologous Prime-Boost COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with Homologous Vaccination Strategy against SARS-CoV-2 Variants
por: Zhang, Ruiqi, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_0jcs08a0hked316u7a9hfdqsr6